Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application; Sigma Aldrich Research Biochemicals, Inc.

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to 21 CFR 1301.33(a), this is notice that on November 19, 2013, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following classes of controlled substances:

Drug Schedule
Cathinone (1235)I
Etorphine HCl (9059)II
Methcathinone (1237)I
Mephedrone(4-Methyl-N-methylcathinone) (1248)I
Aminorex (1585)I
Alpha-ethyltryptamine (7249)I
Lysergic acid diethylamide (7315)I
Tetrahydrocannabinols (7370)I
4-Bromo-2,5-dimethoxyamphetamine (7391)I
4-Bromo-2,5-dimethoxyphenethylamine (7392)I
4-Methyl-2,5-dimethoxyamphetamine (7395)I
2,5-Dimethoxyamphetamine (7396)I
3,4-Methylenedioxyamphetamine (7400)I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)I
3,4-Methylenedioxy-N-ethylamphetamine (7404)I
3,4-Methylenedioxymethamphetamine (MDMA) (7405)I
Dimethyltryptamine (7435)I
Psilocybin (7437)I
5-Methoxy-N,N-diisopropyltryptamine (7439)I
1-[1-(2-Thienyl)cyclohexyl] piperidine (TCP) (7470)I
N-Benzylpiperazine (BZP) (7493)I
MDPV(3,4-Methylenedioxypyrovalerone) (7535)I
Methylone(3,4-Methylenedioxy-N-methylcathinone) (7540)I
Heroin (9200)I
Normorphine (9313)I
Amphetamine (1100)II
Methamphetamine (1105)II
Nabilone (7379)II
1-Phenylcyclohexylamine (7460)II
Phencyclidine (7471)II
Cocaine (9041)II
Codeine (9050)II
Ecgonine (9180)II
Levomethorphan (9210)II
Levorphanol (9220)II
Meperidine (9230)II
Metazocine (9240)II
Methadone (9250)II
Morphine (9300)II
Thebaine (9333)II
Levo-alphacetylmethadol (9648)II
Remifentanil (9739)II
Sufentanil (9740)II
Carfentanil (9743)II
Fentanyl (9801)II

The company plans to manufacture reference standards.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 7, 2014.

Start Signature

Dated: January 15, 2014.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. 2014-02202 Filed 2-3-14; 8:45 am]

BILLING CODE 4410-09-P